How to Capture Growth in the Expanding Metabolic Drug Market
Bringing new metabolic disease therapies, such as GLP-1s, from a promising molecule to patient delivery requires seamless sponsor-CRDMO collaboration.
Interest in the development of new therapies to treat endocrine and metabolic diseases has skyrocketed, driven in part by increased commercial success and medical efficacy of GLP-1 agonists and other incretin hormones used to treat obesity in recent years.
As a result, research and development spending in metabolic disease therapies is now on par with oncology, making it one of the most sought-after areas in the pharmaceutical industry.
In this whitepaper, Dr. Andy Lewis, Chief Scientific Officer, Dr. Andreas Reichl, Senior Drug Development Consultant, and Matthew Paterson, Chief Strategy Officer, share an inside look at what it takes to succeed in this competitive market.
Solutions for early clinical development
Dedicated to early clinical development, Quotient Sciences can help accelerate your molecule to your first-in-human and proof of concept milestones. We also offer a range of exploratory and regulatory-driven Phase 1 clinical pharmacology studies for registration and product labelling purposes.